A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of the NLRP3 Inhibitor Vent-02 in Patients with Mild to Moderate Parkinson’s Disease
Objective: To describe the innovative Phase 2 study design aimed to investigate vent-02 in the treatment of PD. Background: NLRP3 hyperactivation plays a critical role…Bidirectional Relationships Between Frailty and DNAm Age Acceleration and its Mediation Effects on Physical Disability and Mortality
Objective: This study aims to investigate the bidirectional associations between frailty and DNA methylation (DNAm) age acceleration (AgeAccel), and further test whether epigenetic aging mediates…PADOVA: Topline results from a Phase IIb study of prasinezumab in early-stage Parkinson’s disease participants on stable symptomatic treatment
Objective: To evaluate the effect of prasinezumab on slowing down disease progression in participants with early-stage Parkinson’s disease (PD) on stable symptomatic medication. Background: Prasinezumab…Neuroprotective Role of Diosgenin-Loaded Lipid Nanoparticles for Parkinson’s Disease: Pharmacokinetic and Pharmacodynamic Insights
Objective: To develop, optimize, and evaluate diosgenin-loaded solid lipid nanoparticles (DG-SLNs) and nanostructured lipid carriers (DG-NLCs) incorporated into hydrogel formulations (DG-SLN-C and DG-NLC-C) for improved…Peripheral insulin resistance may predict exenatide treatment response in Parkinson’s disease
Objective: To explore if the glucagon-like peptide-1 (GLP-1) receptor agonist, exenatide could modify the course of Parkinson’s disease (PD) and if peripheral insulin resistance (IR) mightdifferentially impact on this. Background: Exenatide…Therapeutic Efficacy of Human Dental Pulp Stem Cells-Derived Exosome-Encased Phloroglucinol In MPTP-Induced Chronic Parkinsonian Rat model: Potential for Disease Modification
Objective: This study aimed to evaluate the therapeutic efficacy of intranasally administered exosome-encased phloroglucinol (Exo-Phl) in a MPTP rat model of PD. Background: Dopaminergic (DA)…Cognitive and Motor Wobbling in Isolated RBD: A Multicentric Study by the International RBD Study Group (IRBDSG)
Objective: To define and characterize clinically fluctuating transition phases from isolated RBD (iRBD) to overt alpha-synucleinopathy. Background: Patients with iRBD often develop motor and non-motor…Beyond Medication: The Potential of Diet in Parkinson’s Management
Objective: To assess the effects of diet and dietary supplements on motor/non-motor symptoms, and disease progression in Parkinson disease (PD). Background: Diet has generally played…A multi-center, randomized, controlled study of the add-on effect of selegiline or zonisamide to L-dopa/DCI therapy in Parkinson’s disease (DATSZ-PD study)
Objective: To investigate the efficacy and safety for neuroprotection and disease modifying effect in selegiline(SL) or zonisamide(ZN) by using UPDRS, PDQ-39 and DAT -SPECT in…A Novel Therapeutic Targeting the tPA-NMDAr Interaction for Parkinson’s Disease
Objective: Glunomab, a monoclonal antibody designed to inhibit the interaction between tissue plasminogen activator (tPA) and the N-methyl-D-aspartate receptor (NMDAr), has demonstrated therapeutic potential across…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- 6
- …
- 22
- Next Page »